TABLE 4.
The mediating effects of inflammatory markers on the relationship between exercise and fatigue.
| Total Fatigue, Estimate (95% CI) | Proportion Mediated (%) | Physical Fatigue, Estimate (95% CI) | Proportion Mediated (%) | |
|---|---|---|---|---|
| Effect of RT-HIIT on fatigue | ||||
| Total effect | −1.25 (−2.58 to 0.09) | −1.48 (−2.98 to −0.02)* | ||
| Indirect effect through CD40-L | −0.01 (−0.34 to 0.12) | 0.8 | −0.03 (−0.49 to 0.11) | 2.0 |
| Indirect effect through IL-6 | −0.40 (−1.11 to −0.04)* | 32.0 | −0.41 (−1.01 to −0.03)* | 27.7 |
| Indirect effect through EGF | −0.006 (−0.29 to 0.14) | 0.5 | −0.03 (−0.41 to 0.08) | 2.0 |
| Indirect effect through TRAIL | −0.13 (−0.69 to 0.04) | 10.4 | −0.13 (−0.78 to 0.06) | 8.8 |
| Indirect effect through CD8a | −0.39 (−1.11 to −0.02)* | 31.2 | −0.39 (−1.20 to −0.004)* | 26.4 |
| Indirect effect through DCN | −0.13 (−0.77 to 0.05) | 10.4 | −0.12 (−0.69 to 0.08) | 8.1 |
| Indirect effect through CCL17 | −0.009 (−0.30 to 0.10) | 0.7 | −0.02 (−0.43 to 0.09) | 1.4 |
| Indirect effect through CASP-8 | −0.05 (−0.52 to 0.06) | 4.0 | −0.07 (−0.60 to 0.06) | 4.7 |
| Indirect effect through ICOSLG | −0.17 (−0.81 to 0.05) | 13.6 | −0.15 (−0.72 to 0.05) | 10.1 |
| Indirect effect through CSF-1 | −0.30 (−0.91 to 0.03) | 24.0 | −0.29 (−0.93 to 0.07) | 19.6 |
| Indirect effect through IFN-γ | −0.22 (−0.86 to 0.07) | 17.6 | −0.24 (−1.00 to 0.08) | 0.16 |
| Indirect effect through IL-10 | −0.03 (−0.36 to 0.56) | 2.4 | −0.06 (−0.78 to 0.26) | 4.1 |
| Indirect effect through FasL | −0.11 (−0.61 to 0.08) | 8.8 | −0.15 (−0.73 to 0.12) | 10.1 |
| Indirect effect through CXCL9 | −0.03 (−0.25 to 0.38) | 2.4 | −0.05 (−0.27 to 0.44) | 3.4 |
| Indirect effect through MIC A/B | −0.24 (−0.68 to 0.02) | 19.2 | −0.23 (−0.73 to 0.01) | 15.5 |
| Effect of AT-HIIT on fatigue | ||||
| Total effect | −1.59 (−2.94 to −0.24)* | −1.60 (−3.12 to −0.09)* | ||
| Indirect effect through CD40-L | −0.05 (−0.51 to 0.21) | 3.1 | −0.11 (−0.64 to 0.17) | 6.9 |
| Indirect effect through IL-6 | −0.13 (−0.60 to 0.18) | 8.2 | −0.12 (−0.64 to 0.16) | 7.5 |
| Indirect effect through EGF | −0.02 (−0.45 to 0.24) | 0.9 | −0.08 (−0.65 to 0.17) | 4.8 |
| Indirect effect through TRAIL | −0.04 (−0.09 to 0.47) | 2.5 | −0.05 (−0.11 to 0.51) | 3.1 |
| Indirect effect through CD8a | −0.22 (−0.82 to 0.03) | 13.8 | −0.22 (−0.95 to 0.06) | 13.8 |
| Indirect effect through DCN | −0.005 (−0.21 to 0.27) | 0.3 | −0.007 (−0.17 to 0.37) | 0.4 |
| Indirect effect through CCL17 | −0.02 (−0.46 to 0.16) | 1.3 | −0.06 (−0.65 to 0.12) | 3.8 |
| Indirect effect through CASP-8 | −0.10 (−0.64 to 0.10) | 6.3 | −0.14 (−0.74 to 0.08) | 8.8 |
| Indirect effect through ICOSLG | −0.06 (−0.53 to 0.11) | 3.8 | −0.06 (−0.49 to 0.08) | 3.8 |
| Indirect effect through CSF-1 | −0.07 (−0.50 to 0.22) | 4.4 | −0.07 (−0.50 to 0.27) | 4.4 |
| Indirect effect through IFN-γ | −0.06 (−0.50 to 0.16) | 3.8 | −0.06 (−0.53 to 0.20) | 3.8 |
| Indirect effect through IL-10 | −0.01 (−0.20 to 0.22) | 0.01 | −0.001 (−0.17 to 0.24) | 0.1 |
| Indirect effect through FasL | −0.01 (−0.37 to 0.18) | 0.6 | −0.006 (−0.40 to 0.30) | 0.4 |
| Indirect effect through CXCL9 | −0.18 (−0.02 to 0.64) | 11.3 | −0.23 (−0.03 to 0.72) | 14.4 |
| Indirect effect through MIC A/B | −0.10 (−0.57 to 0.17) | 6.3 | −0.09 (−0.57 to 0.11) | 5.6 |
*P < 0.05.
CASP-8, caspase-8; CD40-L, CD40 ligand; CSF-1, macrophage colony stimulating factor 1; CXCL9, C-X-C motif chemokine 9; DCN, decorin; FasL, Fas antigen ligand; ICOSLG, ICOS ligand; MIC A/B, MHC class I polypeptide-related sequence A/B; TRAIL, TNF-related apoptosis-inducing ligand.